Lai WV, et al. - In this retrospective, international, multicenter study of afatinib in patients with metastatic or recurrent HER2-mutant lung cancers, researchers characterized clinical course and outcomes. Eligible patients were identified between 2009 and 2017 among seven institutions across Europe, Australia, and North America. In patients with HER2-mutant lung adenocarcinomas, afatinib was found to be modestly active, including responses to previous HER2-targeted treatments after progression. However, the authors concluded that further research into the biology of HER2-mutant lung adenocarcinomas and the development of better HER2-directed treatments is warranted.